The Seattle-based company will bring 300 to 500 jobs to Austin, Texas as it build a multibillion-dollar robotics manufacturing facility.

MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Intuitive Surgical (NASDAQ:ISRG) […]

ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.

Abbott Laboratories stock has delivered a 14.0% total return over the past three years, yet its current checks suggest a mixed valuation picture as the Discounted Cash Flow (DCF) estimate points to meaningful upside while market multiples look closer to fair. A 14.0% return over three years indicates that long term holders have seen moderate gains, even though shorter term returns have recently been weaker. Partnerships such as supplying sensors for MiniMed Flex and the Lingo data...

This top dividend ETF is still a reliable long-term income investment.

Abbott Laboratories (NYSE:ABT) is supplying its Instinct sensor for MiniMed's newly shipped app-controlled insulin pump in the U.S. The system pairs what MiniMed describes as the world's smallest app-controlled insulin pump with Abbott's smallest wearable glucose sensor. The commercial rollout broadens Abbott's role in diabetes care devices through integration into a widely accessible pump platform. The launch reflects wider industry adoption of wearable health technology that supports more...

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

On August 11, medtech leader Abbott Laboratories (NYSE:ABT) and tech behemoth Alphabet Inc. (NASDAQ:GOOG) announced a multi-year partnership to unite continuous glucose monitoring with consumer AI. The collaboration embeds data from Abbott’s non-prescription Lingo biowearable directly into the Google Health app, combining real-time metabolic insights with Google’s AI Health Coach to deliver personalized habit recommendations […]

AbbVie has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per share while the index has gained 13.5%.

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.